This article is more than 5 years old. Information may no longer be current.
Study: Highest symptom-free concentration of atropine may be 0.02%
Click Here to Manage Email Alerts
The highest concentration of atropine that does not result in significant symptoms from pupillary dilation and accommodative paralysis was found to be 0.02%, according to a recently published study.
A 3 x 3 phase 1 clinical trial paradigm was used in 12 subjects. Accommodation was measured by pushouts, while pupillary dilation was measured by photography.
Previously, the study authors established criteria for comfort as 5 D or more of residual amplitude of accommodation, less than or equal to a 3-mm pupillary difference between the eyes and a report of minimal symptoms of near vision blur or outside photophobia.
At 0.02% concentration levels in the study, mean pupillary dilation was 3 mm and mean accommodative amplitude was 8 D, and no significant symptoms from pupillary dilation and accommodative paralysis were observed.
Further, reduction of the concentration of atropine from 0.02 to 0.01% did not seem to result in a decrease in clinical signs or symptoms associated with atropine.
“This would be an appropriate starting point in evaluating a low dosage of atropine to slow myopic progression,” the study authors said.
Click Here to Manage Email Alerts